Mineralys Therapeutics, Inc. Financials
This page shows Mineralys Therapeutics, Inc. (MLYS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Mineralys Therapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Mineralys Therapeutics, Inc. generates $0.94 in operating cash flow (-$166.3M OCF vs -$177.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Mineralys Therapeutics, Inc.'s EBITDA was -$192.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 127.2% from the prior year.
Mineralys Therapeutics, Inc. generated -$166.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 105.0% from the prior year.
Mineralys Therapeutics, Inc. reported -$177.8M in net income in fiscal year 2024. This represents a decrease of 147.3% from the prior year.
Mineralys Therapeutics, Inc. earned $-3.66 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 83.9% from the prior year.
Mineralys Therapeutics, Inc. held $114.1M in cash against $0 in long-term debt as of fiscal year 2024.
Mineralys Therapeutics, Inc. had 50M shares outstanding in fiscal year 2024. This represents an increase of 21.2% from the prior year.
Mineralys Therapeutics, Inc. invested $168.6M in research and development in fiscal year 2024. This represents an increase of 139.6% from the prior year.
Mineralys Therapeutics, Inc. invested $96K in capex in fiscal year 2024, funding long-term assets and infrastructure.
MLYS Income Statement
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $31.4M | N/A | $22.5M | N/A | $6.1M |
| SG&A Expenses | $9.7M | N/A | $3.8M | N/A | $1.4M |
| Operating Income | -$41.1M | N/A | -$26.3M | N/A | -$7.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$36.9M | N/A | -$22.8M | N/A | -$6.7M |
| EPS (Diluted) | $-0.52 | N/A | $-0.57 | N/A | $-1.29 |
MLYS Balance Sheet
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 |
|---|---|---|---|---|---|
| Total Assets | $599.9M+138.4% | $251.6M-9.3% | $277.6M+142.5% | $114.4M | N/A |
| Current Assets | $599.8M+140.8% | $249.1M-6.1% | $265.4M+135.2% | $112.8M | N/A |
| Cash & Equivalents | $217.6M+341.3% | $49.3M-42.9% | $86.3M-1.6% | $87.7M+79.1% | $49.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $23.5M+124.4% | $10.5M-22.6% | $13.5M-91.9% | $166.7M | N/A |
| Current Liabilities | $23.5M+124.4% | $10.5M-22.6% | $13.5M+67.9% | $8.1M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $576.4M+139.0% | $241.2M-8.7% | $264.0M+605.1% | -$52.3M-20.4% | -$43.4M |
| Retained Earnings | -$424.9M-240.7% | -$124.7M-24.3% | -$100.3M-90.0% | -$52.8M | N/A |
MLYS Cash Flow Statement
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$28.9M+0.4% | -$29.0M-52.3% | -$19.0M-86.8% | -$10.2M-45.8% | -$7.0M |
| Capital Expenditures | $0 | $0 | $0 | N/A | N/A |
| Free Cash Flow | -$28.9M+0.4% | -$29.0M-52.3% | -$19.0M | N/A | N/A |
| Investing Cash Flow | -$150.5M-1760.6% | -$8.1M-301.9% | $4.0M-92.0% | $50.0M+169.7% | -$71.8M |
| Financing Cash Flow | $295.2M+398802.7% | $74K-59.8% | $184K+117.2% | -$1.1M-90.4% | -$561K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A |
MLYS Financial Ratios
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.2% | N/A | -8.2% | N/A | N/A |
| Current Ratio | 25.50+1.7 | 23.76+4.2 | 19.59+5.6 | 13.98 | N/A |
| Debt-to-Equity | 0.040.0 | 0.040.0 | 0.05+3.2 | -3.19 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Mineralys Therapeutics, Inc. profitable?
No, Mineralys Therapeutics, Inc. (MLYS) reported a net income of -$177.8M in fiscal year 2024.
What is Mineralys Therapeutics, Inc.'s earnings per share (EPS)?
Mineralys Therapeutics, Inc. (MLYS) reported diluted earnings per share of $-3.66 for fiscal year 2024. This represents a -83.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mineralys Therapeutics, Inc.'s EBITDA?
Mineralys Therapeutics, Inc. (MLYS) had EBITDA of -$192.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mineralys Therapeutics, Inc.'s free cash flow?
Mineralys Therapeutics, Inc. (MLYS) generated -$166.4M in free cash flow during fiscal year 2024. This represents a -105.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mineralys Therapeutics, Inc.'s operating cash flow?
Mineralys Therapeutics, Inc. (MLYS) generated -$166.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mineralys Therapeutics, Inc.'s total assets?
Mineralys Therapeutics, Inc. (MLYS) had $205.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Mineralys Therapeutics, Inc.'s capital expenditures?
Mineralys Therapeutics, Inc. (MLYS) invested $96K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Mineralys Therapeutics, Inc. spend on research and development?
Mineralys Therapeutics, Inc. (MLYS) invested $168.6M in research and development during fiscal year 2024.
How many shares does Mineralys Therapeutics, Inc. have outstanding?
Mineralys Therapeutics, Inc. (MLYS) had 50M shares outstanding as of fiscal year 2024.
What is Mineralys Therapeutics, Inc.'s current ratio?
Mineralys Therapeutics, Inc. (MLYS) had a current ratio of 14.02 as of fiscal year 2024, which is generally considered healthy.
What is Mineralys Therapeutics, Inc.'s debt-to-equity ratio?
Mineralys Therapeutics, Inc. (MLYS) had a debt-to-equity ratio of 0.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mineralys Therapeutics, Inc.'s return on assets (ROA)?
Mineralys Therapeutics, Inc. (MLYS) had a return on assets of -86.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mineralys Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Mineralys Therapeutics, Inc. (MLYS) had $114.1M in cash against an annual operating cash burn of $166.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mineralys Therapeutics, Inc.'s Piotroski F-Score?
Mineralys Therapeutics, Inc. (MLYS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mineralys Therapeutics, Inc.'s earnings high quality?
Mineralys Therapeutics, Inc. (MLYS) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.